Edited by Jan Kitajewski
This Vascular Cell review series, developed by leaders in pharmaceutical and academic cancer research, presents an update on efforts to block tumor growth by targeting the Dll4/Notch pathway. This pathway is active during tumor angiogenesis and in cancer stem cells. The excitement about the effective targeting of tumors using this approach and the challenge of minimizing adverse responses are key points of discussion.
Anti-angiogenesis agents and the identification of cancer stem-like cells (CSC) are opening new avenues for targeted cancer therapy. Recent evidence indicates that angiogenesis regulatory pathways and developm...
Tumor angiogenesis is an important target for cancer therapy, with most current therapies designed to block the VEGF signaling pathway. However, clinical resistance to anti-VEGF therapy highlights the need for...
DLL4 is a ligand for the Notch family of receptors. DLL4 has many important functions in normal development and tissue homeostasis, including roles in the immune system, the gastro-intestinal tract, and in vas...
DLL4-mediated NOTCH1 signaling represents an essential pathway for vascular development and has emerged as an attractive target for angiogenesis-based cancer therapies. However, newly reported toxicity finding...